Topic:

Europe

Latest Headlines

Latest Headlines

Consort Medical strikes $374M deal to buy Aesica

Consort Medical has placed a big bet on the convergence of drug and device production services, striking a £230 million ($374 million) deal to buy European contract manufacturer Aesica Pharmaceuticals. 

Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.

Gilead nears EU approval for the next big thing in hep C

Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections.

New group wants to attract pharma manufacturing to the U.K.

A new Medicines Manufacturing Industry Partnership has been jointly established by the Association of the British Pharmaceutical Industry and the BioIndustry Association.

Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet

German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.

EU IPOs: Up on '13, down on U.S., CRUK, MedImmune to run lab, Clal sues Hyperion

Welcome to the latest edition of our weekly  EuroBiotech Report.

Molecular Partners plots a $134M IPO for some R&D me-time

On the heels of some A-list biopharma partnerships, Switzerland's Molecular Partners is looking to double down on its in-house projects, swinging for a $134 million IPO to help pay its way.

Cubist makes Euro landfall with a $400M purse for antibiotics R&D

The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.

Novo Nordisk wins EU approval for a diabetes combo with billion-dollar potential

Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.

Dutch VC opens €65M cancer fund, Affimed IPO falls short, Evotec begins legal action

In this week's EuroBiotech Report, cash-starved European cancer startups had reason to cheer when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool--which could rise to €100 million--in up to 15 early-stage biotechs. And more.